Navigation Links
Genetic Substudy Shows Fewer Major Cardiovascular Events With Ticagrelor (BRILINTA) Regardless of Relevant Genetic Variability in ACS Patients
Date:8/29/2010

WILMINGTON, Del., Aug. 29 /PRNewswire-FirstCall/ -- A new genetic substudy of PLATO (A Study of PLATelet Inhibition and Patient Outcomes) showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes (ACS) patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA™), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel. The substudy is the first to look at both efficacy and bleeding endpoints of ACS patients treated with ticagrelor who carry variations in the CYP2C19 and ABCB1 genes. The data were presented today at the European Society of Cardiology (ESC) congress in Stockholm, Sweden and simultaneously published in The Lancet.    

(Logo: http://photos.prnewswire.com/prnh/20091027/PH99766LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO)

CYP2C19

Regardless of the CYP2C19 genotype, the primary outcome occurred less often with ticagrelor versus clopidogrel (interaction p=0.46). Ticagrelor event rates were 8.6% per year in carriers  and 8.8% per year in non-carriers of CYP2C19 loss-of-function genotype. For clopidogrel patients that carried the CYP2C19 loss-of-function alleles, there was a 11.2% per year event rate, compared to 10.0% per year for patients without the loss of function allele. Similar to the overall PLATO study, total major bleeding did not significantly differ between ticagrelor and clopidogrel regardless of CYP2C19 genotype.

ABCB1

The genetic substudy also investigated ticagrelor and clopidogrel treatment outcomes in the three genetic groupings of the ABCB1 gene group; these were defined as high, intermediate and low expressions of ABCB1, respectively.  The primary efficacy event rates for ticagrelor were: 9.5% p
'/>"/>

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Genetics Determine Optimal Drug Dose of Common Anticoagulant
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
6. Genetic Differences Predict Anti-Inflammatory Benefits From Nutritional Products
7. 454 Sequencing(TM) in Science Today: Researchers Uncover a Genetic Basis for Different Social Behaviors in Wasps
8. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. American Fertility Association Calls for Expanded Research to Advance New Technology to Screen Embryos for Genetic Abnormalities
11. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... PARK CITY, Utah , Sept. 17, 2014 ... into an exclusive global licensing and collaboration agreement ... develop and commercialize NuView,s investigative genomic-based diagnostic biomarker ... The agreement also includes all other future diagnostic-imaging ... compound for in-vivo therapeutic delivery and in-vitro urine ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
(Date:9/17/2014)... MILL VALLEY, Calif. , Sept. ... today announced a partnership in the fight against ... the Sarcoma Alliance Suzanne Renee Leider Memorial Assistance ... financial assistance to reimburse sarcoma patients for expenses ... a sarcoma specialist. Scientific literature reinforces the importance ...
Breaking Medicine Technology:NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 2Champions Oncology Partners with Sarcoma Alliance to Bring Personalized Treatment Options to Sarcoma Patients 3
... , BOSTON, Nov. 23 AMICAS, Inc. ... management solutions, today announced that it will highlight its enterprise ... America (RSNA) annual meeting from November 29 to December 4 ... in booth #7124. , (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) ...
... , MINNEAPOLIS, Nov. 23 BridgePoint Medical announced ... for its coronary and peripheral Chronic Total Occlusion (CTO) ... and the Stingray® CTO Re-Entry System. The BridgePoint ... designed to navigate highly diseased arteries in preparation for ...
Cached Medicine Technology:AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 2AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 3BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 2BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 3
(Date:9/17/2014)... 2014 Promising new research published in ... light on the potential ability of ketones to support ... The study shows that brain hypometabolism ... by impaired glucose uptake and/or utilization, and results suggest ... , The study, by the Research Center on Aging ...
(Date:9/17/2014)... September 16, 2014) A study led by ... the chemotherapy dose threshold below which male childhood ... production. The study appears in September 17 edition ... By clarifying which patients are at highest risk ... the findings to eventually increase use of pre-treatment ...
(Date:9/17/2014)... wine leads to an explosion of flavours in your mouth. ... that can mimic what happens in your mouth when you ... of dryness in the wine. , When wine growers turn ... of processes to bring out the desired flavour in the ... part of the taste is known in wine terminology as ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 A  recent ... of a 24-year-old man named Advait Thakur who had ... caused by degenerative disc disease. This disease led to ... his nerve roots and causing severe pain. Leading spine ... and how it can lead to such severe pain, ...
(Date:9/17/2014)... NetDimensions (AIM: NETD; OTCQX: NETDY), a global ... the opening of the 2014 Next Steps user conference ... very excited to meet up in Chicago again this ... Steps from our clients and partners, which shows how ... look forward to some very engaging and fun days ...
Breaking Medicine News(10 mins):Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 2Health News:Journal of Alzheimer's Disease Publishes New Study Suggesting Ketones have Potential to Compensate for Brain Energy Deficit 3Health News:Improved risk identification will aid fertility preservation in young male cancer patients 2Health News:Improved risk identification will aid fertility preservation in young male cancer patients 3Health News:Nanoscience makes your wine better 2Health News:Nanoscience makes your wine better 3Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 2Health News:24-Year-Old Back in College After Degenerative Disc Disease Kept Him Out 3Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3
... By Steven Reinberg HealthDay Reporter , THURSDAY, Sept. ... phone use and texting soared in the space of three ... Texting alone caused more than 16,000 deaths in car accidents ... involving cell phones and texting while driving rose 28 percent ...
... S. Bloomberg Faculty of Nursing professor, Dr. Diane Doran, ... will help protect the safety of over 900,000 Canadians ... day. The Canadian Patient Safety Institute and its ... research competition drawing some of Canada,s leading healthcare researchers. ...
... Reporter , THURSDAY, Sept. 23 (HealthDay News) -- It was ... dream. He,d just been plucked from his life as ... the National Basketball Association,s Dallas Mavericks, summer training camp after ... But a small on-court collision with another player led to ...
... to boost research on women,s health over the last two ... among women due to cardiovascular disease, breast cancer, and cervical ... The effort has yielded less but still significant progress ... women, added the committee that wrote the report. ...
... pathology at the University of California, San Diego School ... the Moores UCSD Cancer Center, has been named the ... bestowed by the Metastasis Research Society, an international, non-profit ... was honored at a recent joint meeting of the ...
... and Tallinn, Estonia (September 23, 2010) At an international ... Global TB Vaccine Foundation announced it will initiate a clinical ... led by researchers at Saint Louis University in St. Louis, ... Global Forum on TB Vaccine Development. Building on ...
Cached Medicine News:Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 3Health News:Experimental Leukemia Drug Proves a Slam Dunk 4Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 2Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 3Health News:David Cheresh receives top award for cancer metastasis research 2Health News:New TB vaccine enters clinical testing 2
... developed the world's first 8-channel ... completely AC powered in 1951. ... a number of standard setting ... systems, such as a Windows ...
... you're getting an ambulatory and a clinical EEG ... Mobee O2 can be used for ambulatory EEG ... or in-lab sleep studies. And both feature 32 ... placement. The Mobee O2 includes the additional enhancement ...
... The VISULAS 690s is the ... the instrument of choice for ... clinical trials, Carl Zeiss has ... in laser manufacturing to create ...
... Humphrey Lens Analyzers Model 350 and ... most comprehensive lensometry for your practice. ... Analyzer (LA) gives fast and accurate ... lenses, prism lenses, contact lenses, polycarbonate ...
Medicine Products: